Takeo Dochi

Disease burden and treatment patterns of paroxysmal nocturnal hemoglobinuria in Japan: a real-world survey

Masatoshi Sakurai, Yasutaka Ueda, Naoshi Obara, Michel Kroes et autres

This study aimed to determine the clinical profile and disease burden of patients with paroxysmal nocturnal hemoglobinuria (PNH) in Japan using real-world data from the Adelphi Real World PNH Disease Specific Programme (DSP)™, a cross-sectional survey conducted between January and December 2022. …

jp, ch, gb (code pays fourni par la source)

The Association between Blood Cell Counts and Thrombotic Events in Japanese Patients with Polycythemia Vera: A Retrospective Database Study

Kazuya Shimoda, Hideo Yasunaga, Yuka Sugimoto, Hidetoshi Uenaka et autres

Introduction: The primary goal of therapy for polycythemia vera (PV) is the prevention of thrombotic events (TE). Several studies conducted in the United States and Europe have indicated that elevated hematocrit (HCT) and white blood cell count (WBC) are associated with an …

jp, ch (code pays fourni par la source)

Introduction of Chimeric Antigen Receptor T-cell therapy, Tisagenlecleucel in Japan

Yuki Fujiwara, Jihyun Park, Takeo Dochi, Yoshie Tsurumaki

2019年3月、日本で初めて免疫細胞療法であるキメラ抗原受容体T細胞療法（chimeric antigen receptor-T cell therapy：CAR-T細胞療法）、チサゲンレクルユーセル（製品名；キムリア®点滴静注、ノバルティス）が承認された。チサゲンレクルユーセルの適応は、再発または難治性のCD19陽性のB細胞性急性リンパ芽球性白血病（B-cell acute lymphoblastic leukemia：B-ALL）および、再発または難治性のCD19陽性びまん性大細胞型B細胞リンパ腫（diffuse large B-cell lymphoma：DLBCL）である。チサゲンレクルユーセルは、患者自身のT細胞を原材料とする再生医療等製品であり、白血球アフェレーシスにより採取したT細胞にレンチウイルスベクターを用いてキメラ抗原受容体（chimeric antigen receptor： CAR）遺伝子を導入して製造される。今回の承認は、再発または難治性のCD19陽性のB-ALLとDLBCLを対象とした国際多施設共同第II相試験（ELIANA試験、JULIET試験）の結果に基づいている。このCAR-T細胞療法は、高度な細胞製造技術はもちろん、複雑な製造工程を厳格に管理する体制が求められている。

jp, ch, gb (code pays fourni par la source)

Trametinib suppresses HIV-1 replication by interfering with the disassembly of human immunodeficiency virus type 1 capsid core

Takeo Dochi, Ayano Akita, Naoki Kishimoto, Nobutoki Takamune et autres

jp (code pays fourni par la source)

MEK/ERKsignaling cascadeを介するHIV脱殻過程の分子制御に関する研究

Takeo Dochi

(4P-280)Phosphorylation-regulated mechanism of HIV uncoating and development of novel antiretroviral therapy.

Takeo Dochi

Phosphorylation of human immunodeficiency virus type 1 capsid protein at serine 16, required for peptidyl-prolyl isomerase-dependent uncoating, is mediated by virion-incorporated extracellular signal-regulated kinase 2

Takeo Dochi, Takashi Nakano, Mutsumi INOUE, Nobutoki Takamune et autres

We reported previously that Pin1 facilitates human immunodeficiency virus type 1 (HIV-1) uncoating by interacting with the capsid core through the phosphorylated Ser(16)-Pro(17) motif. However, the specific kinase responsible for Ser(16) phosphorylation has remained unknown. Here, we showed that virion-associated extracellular signal-regulated …

jp (code pays fourni par la source)

Uncoating of Human Immunodeficiency Virus Type 1 Requires Prolyl Isomerase Pin1

Shogo Misumi, Mutsumi INOUE, Takeo Dochi, Naoki Kishimoto et autres

The process by which the human immunodeficiency virus type 1 (HIV-1) conical core dissociates is called uncoating, but not much is known about this process. Here, we show that the uncoating process requires the interaction of the capsid (CA) protein with the …

jp (code pays fourni par la source)